Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-17-033946
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-05-19 15:32:48
Reporting Period:
2017-04-17
Filing Date:
2017-05-19
Filing Date Changed:
2017-05-19
Accepted Time:
2017-05-19 16:32:48
Original Submission Date:
2017-04-18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1419600 Flexion Therapeutics Inc FLXN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1598099 Neil Bodick C/o Flexion Therapeutics, Inc.
10 Mall Road, Suite 301
Burlington MA 01803
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-04-17 5,000 $2.52 64,937 No 4 M Direct
Common Stock Disposition 2017-04-17 4,800 $28.20 60,137 No 4 S Direct
Common Stock Disposition 2017-04-17 200 $28.86 59,937 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2017-04-17 5,000 $0.00 5,000 $2.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
44,302 2022-08-28 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 388,683 Indirect By Versant Development Fund III, LLC
Footnotes
  1. This Form 4 is being amended to include the option exercise that occurred in connection with the reported sale and to correct the number of securities beneficially owned following the reported transaction.
  2. Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted June 23, 2016.
  3. The weighted average sale price for the transaction reported was $28.20, and the range of prices were between $27.77 and $28.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. The weighted average sale price for the transaction reported was $28.86, and the range of prices were between $28.83 and $28.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
  6. The stock option is fully vested and exercisable.